These findings emphasize that AURKA may facilitate HSC activation and exacerbate liver fibrosis through the Wnt/β-catenin pathway, highlighting its potential as a therapeutic target for liver fibrosis with minimal side effects. This evidence concerns the gene AURKA and Hepatic fibrosis.